clinical trial · NCT07544589
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Dispatch Biotherapeutics·phase1·recruiting·n = 66
Colorectal CancerGastric AdenocarcinomaEsophageal AdenocarcinomaGastroesophageal AdenocarcinomaDISP-10
brief summary
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
started
Apr 1, 2026
primary completion
Apr 1, 2046
completion
Apr 1, 2046
last updated
May 29, 2026
official title
A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants With Advanced Gastrointestinal Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol